郭晓东孟繁平△ 熊璐.HIF-lα的表达在肝移植后肝癌复发与转移中的意义[J].现代生物医学进展英文版,2011,11(5):876-879. |
HIF-lα的表达在肝移植后肝癌复发与转移中的意义 |
Clinical significance of HIF-lαexpression in recurrence and metastasisof patients with hepatocellular carcinoma undergoingliver transplantation |
|
DOI: |
中文关键词: 肝肿瘤 肝移植 复发 转移 低氧诱导因子-lα |
英文关键词: Hepatocellular carcinoma Liver transplantation Recurrence Metastasis Hypoxia-inducible factor-1α |
基金项目:国家自然科学基金青年基金项目( 30901795) |
|
Hits: 799 |
Download times: 1043 |
中文摘要: |
目的:探讨肝癌组织中低氧诱导因子-lα(HIF-lα)表达与肝癌行肝移植治疗后肿瘤复发与转移之间的关系。方法:选择肝癌
行全肝移植患者45 例,应用免疫组化方法检测其切除的肝癌组织、癌旁组织中HIF-lα 的表达,分析其表达与移植后肝癌复发与
转移之间的关系和意义。结果:肝癌组织中HIF-1α 阳性表达率明显高于癌旁组织(X2=6.39,P<0.01)。HIF-1α 在肝癌组织中的表达
与肿瘤直径、TNM 分期、有无淋巴结转移、有无门静脉癌栓及肿瘤播散灶密切相关(P<0.01)。复发转移组和未复发转移组HIF-1α
阳性表达率比较,差异存在显著性(X2=8.46,P<0.01)。Cox 回归多因素分析表明HIF-1α 高表达是影响肝癌患者肝移植后肿瘤复发
和转移的独立预后因素(P<0.01)。结论:HIF-1α 蛋白有望成为一个预测肝癌患者肝移植后复发和转移的重要指标。 |
英文摘要: |
Objective: To investigate the expression of HIF-lα expression in the recurrence and metastasis of patients with
hepatocellular carcinoma undergoing liver transplantation, and discuss their relationship. Methods: The expression of HIF-lα protein was
detected with immunohistochemical analysis in 45 cases of HCC and pericarcinoma tissues and the relationship between the expression
of HIF-lα with the recurrence and metastasis were explored. Results: The positive expression rate of HIF-lα protein in HCC was
significantly higher than that in pericarcinoma tissues (X2=6.39,P<0.01). The expression of HIF-lα was positively related to TNM type,
lymph node metascasis and portal vein cancer-embolus(P<0.01). The positive expression rate of HIF-lα protein was different significantly
between recurrence and metastasis positive group with recurrence and metastasis negative group(X2=8.46,P<0.01). The Cox proportional
hazards model showed that HIF-lα protein was an independent factor of the recurrence and metastasis for HCC patients after liver
transplantation (P<0.01). Conclusions: The expression of HIF-lα protein may act as markers predicting the recurrence and metastasis of
patients with hepatocellular carcinoma undergoing liver transplantation. |
View Full Text
View/Add Comment Download reader |
Close |